German pharmaceuticals company
POPULARITY
Categories
134 episodes with Bayer
213 episodes with Bayer
126 episodes with Bayer
52 episodes with Bayer
98 episodes with Bayer
27 episodes with Bayer
44 episodes with Bayer
50 episodes with Bayer
72 episodes with Bayer
44 episodes with Bayer
38 episodes with Bayer
26 episodes with Bayer
106 episodes with Bayer
34 episodes with Bayer
38 episodes with Bayer
59 episodes with Bayer
20 episodes with Bayer
21 episodes with Bayer
27 episodes with Bayer
16 episodes with Bayer
34 episodes with Bayer
33 episodes with Bayer
21 episodes with Bayer
60 episodes with Bayer
25 episodes with Bayer
20 episodes with Bayer
14 episodes with Bayer
18 episodes with Bayer
15 episodes with Bayer
24 episodes with Bayer
23 episodes with Bayer
17 episodes with Bayer
13 episodes with Bayer
16 episodes with Bayer
19 episodes with Bayer
208 episodes with Bayer
10 episodes with Bayer
40 episodes with Bayer
15 episodes with Bayer
20 episodes with Bayer
7 episodes with Bayer
14 episodes with Bayer
5 episodes with Bayer
10 episodes with Bayer
6 episodes with Bayer
17 episodes with Bayer
9 episodes with Bayer
163 episodes with Bayer
12 episodes with Bayer
6 episodes with Bayer
17 episodes with Bayer
9 episodes with Bayer
9 episodes with Bayer
15 episodes with Bayer
11 episodes with Bayer
9 episodes with Bayer
9 episodes with Bayer
9 episodes with Bayer
9 episodes with Bayer
10 episodes with Bayer
10 episodes with Bayer
13 episodes with Bayer
5 episodes with Bayer
6 episodes with Bayer
3 episodes with Bayer
8 episodes with Bayer
5 episodes with Bayer
21 episodes with Bayer
7 episodes with Bayer
3 episodes with Bayer
6 episodes with Bayer
8 episodes with Bayer
4 episodes with Bayer
24 episodes with Bayer
5 episodes with Bayer
8 episodes with Bayer
8 episodes with Bayer
8 episodes with Bayer
12 episodes with Bayer
12 episodes with Bayer
7 episodes with Bayer
5 episodes with Bayer
6 episodes with Bayer
6 episodes with Bayer
6 episodes with Bayer
13 episodes with Bayer
17 episodes with Bayer
7 episodes with Bayer
5 episodes with Bayer
5 episodes with Bayer
6 episodes with Bayer
6 episodes with Bayer
11 episodes with Bayer
5 episodes with Bayer
6 episodes with Bayer
7 episodes with Bayer
5 episodes with Bayer
4 episodes with Bayer
6 episodes with Bayer
6 episodes with Bayer
4 episodes with Bayer
10 episodes with Bayer
10 episodes with Bayer
10 episodes with Bayer
5 episodes with Bayer
3 episodes with Bayer
5 episodes with Bayer
6 episodes with Bayer
6 episodes with Bayer
6 episodes with Bayer
5 episodes with Bayer
5 episodes with Bayer
3 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
6 episodes with Bayer
6 episodes with Bayer
9 episodes with Bayer
9 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
10 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
4 episodes with Bayer
8 episodes with Bayer
8 episodes with Bayer
8 episodes with Bayer
8 episodes with Bayer
8 episodes with Bayer
6 episodes with Bayer
6 episodes with Bayer
4 episodes with Bayer
8 episodes with Bayer
79 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
7 episodes with Bayer
3 episodes with Bayer
5 episodes with Bayer
5 episodes with Bayer
5 episodes with Bayer
5 episodes with Bayer
3 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
3 episodes with Bayer
7 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
3 episodes with Bayer
2 episodes with Bayer
2 episodes with Bayer
3 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
5 episodes with Bayer
2 episodes with Bayer
4 episodes with Bayer
3 episodes with Bayer
7 episodes with Bayer
2 episodes with Bayer
4 episodes with Bayer
4 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
5 episodes with Bayer
3 episodes with Bayer
9 episodes with Bayer
9 episodes with Bayer
4 episodes with Bayer
6 episodes with Bayer
61 episodes with Bayer
4 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
3 episodes with Bayer
This week: Sarah Rosenkranz and Bettina Fafengut, from the product specialist team at testing and certifiers the Hohenstein Group, talk with Ian Welsh and unpack the OEKO-TEX organic cotton certification. As consumer demand for transparency grows, they highlight how empowering buyers with product certainty can raise the bar on both organic integrity and chemical safety. Plus: some quick fire insights from the recent packaging innovation forum in Amsterdam with Bayer's head of packaging sustainability, Keiko Tago, talking with Ian about the complex realities of flexible packaging. And, Nescafé achieves regen ag target; World Refill Day spotlights reuse gaps; and, France targets fast fashion with new law, in the news digest with Ellen Atiyah. Host: Ian Welsh Join the conversation at the sustainable packaging innovation forum, taking place in Chicago on 28-29 October. Click here for information on how to get involved.
This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease risk: Framingham Heart Study insights Sudden death in female athletes Mythbusters: Owning a pet reduces the risk of heart disease Host: Susanna Price Guests: Carlos Aguiar, Sabiha Gati, Vasan Ramachandran Want to watch that episode? Go to: https://esc365.escardio.org/event/1809 Want to watch that extended interview on sudden death in athletes? Go to: https://esc365.escardio.org/event/1809?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. The ESC is not liable for any translated content of this video.The English-language always prevails. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel, Susanna Price and Vasan Ramachandran have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Susanna Price Guest: Sabiha Gati Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1809?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1809 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Hello Rank Squad!Today we're diving back into the murky depths of the transfer market, and looking at some of the potential deals that are being discussed right now. It's a seller's market, in so many ways, and that often means that teams will overpay for players - whether through a gamble on a major talent, a burning need to fill a gap, or because they're absolutely hellbent on trying to turn things around after a tough season the year before. We look at five deals that feel like they might be a big step, with Dean suggesting them, and Jack generally arguing about why it's actually a pretty good bit of business - for a variety of different price tags and reasonings. Before that, we get stuck into the Club World Cup, hear about Dean's experiences on the ground and Jack's ones watching from across the Atlantic, and try to work out what we can learn from the tournament a year out from the 2026 World Cup.It's Ranks! And remember, if you'd like more from the Rank Squad, including extra podcasts every Monday and Friday (including our weekly Postbox taking a look at the whole weekend of football) and access to our brilliant Discord community, then why not join us here on Patreon?
Sermon delivered on Most Holy Trinity Sunday, 2025, in Hammond, Louisiana and Richmond, Texas. Epistle: Rom. 11, 33-36. Gospel: St. Matthew 28, 18-20.
It has now been about a year since Bayer suddenly shut down Care/of…the personalized nutrition brand it acquired in 2020. So, with hindsight providing us 20/20 vision…what can the supplement industry learn about this intense “rise and fall” business story? And you might be thinking, "aren't we too late to learn from the Care/of vitamins business story?" Though, anyone even remotely paying close attention to either the enormous shift in supplement industry marketplace dynamics, the complex (and ever-changing) world of personalized nutrition, and/or the ongoing turnaround efforts at one of the largest players in pharmaceuticals, consumer health, and crop science…knows patience was required to create decisive confident statements about this specific business event. So, my latest first principles thinking content will explore what really happened at Care/of and examine if it has broader implications to what was dubbed by many insider experts and (and mainstream news) sources as the “future of wellness.” Did the Bayer “billion-dollar consumer health brand or bust” mentality cause it? Was it an internal Care/of strategic failures? Or has personalized nutrition been overhyped and will never provide substantial long-term market attractiveness?
The World Organization for Animal Health recently adopted an African Swine Fever vaccine standard to help control the disease, and after spring planting, ag producers should make an appointment with their county Farm Service Agency to complete crop acreage reports before the deadline.
The World Organization for Animal Health recently adopted an African Swine Fever vaccine standard to help control the disease, and after spring planting, ag producers should make an appointment with their county Farm Service Agency to complete crop acreage reports before the deadline.
https://www.youtube.com/watch?v=YchKm3DnUFo Podcast Audio: In this episode of The Ayn Rand Institute Podcast, Onkar Ghate and Ben Bayer discuss the ongoing mass protests in Los Angeles and how the Trump administration's response also shows a disregard for the rule of law. Among the topics covered: The scale of the violence; Evidence that the rioters do not care about immigrants' individual rights; Why the right to peaceably assemble does not imply a right to mass protest; The bad jurisprudence that supports the alleged right to mass protest; The lawlessness of Trump's immigration policies; What a proper response to Trump's lawless immigration policy looks like. Recommended in this podcast are The Ayn Rand Lexicon's entry on free speech, Ghate and Bayer's article “Ending Campus Protests Protects Free Speech,” and Bayer's article “The Specter of Lawlessness Is Darker than You Think.” The podcast was recorded on June 9, 2025 and posted on June 11, 2025. Listen and subscribe wherever you get your podcasts. Watch archived podcasts here.
De Jeroen Leenders Experience Live 30 April 2024, Club Haug, Rotterdam. Word lid op YouTube en kijk de video. Log in met jouw persoonlijke YouTube-account vanop een laptop of PC en volg deze link: https://www.youtube.com/channel/UCl7CNw3jWIMP_Ctk-7n13Sw/join Volgende live- show in Rotterdam on https://www.comedyclubhaug.com/shows #jeroenleendersexperience (0:00) Intro (0:46) Timide Arrogantie (5:46) Civitas Christiana (7:58) Indië (11:04) Lekker weertje (Arie Fazant I) (12:18) Ducktape Toiletrol (Jo Ceunen FBm) (15:54) Bayer (18:55) Houten bestek (Martijn Telma S) (22:05) Vier op een scooter (Kevin Romero FBm) (24:18) Tegenspreken (29:46) Kindermisbruik Light (Tom Van den Abeele S) (31:00) Waar is Fons? (35:27) Voice memo's (42:08) Overroepen (45:55) Oorlog op voorwaarden (51:53) Geen stroom (55:15) Zonnebrand is nep (1:00:19) Frites (1:00:51) Casino (1:06:07) UFO's YouTube: https://www.youtube.com/channel/UCl7CNw3jWIMP_Ctk-7n13Sw/join Speellijst & info: http://www.jeroenleenders.be Instagram: https://www.instagram.com/the_jeroen_leenders_experience/ Facebook: https://www.facebook.com/www.jeroenleenders.be Twitter: https://twitter.com/jeroen_leenders Spotify: https://open.spotify.com/show/5I6B88nVw4wyxWqh331899 YouTube: https://www.youtube.com/channel/UCl7CNw3jWIMP_Ctk-7n13Sw/join iTunes: https://podcasts.apple.com/nl/podcast/jeroen-leenders-experience/id1370129605 Deezer: https://www.deezer.com/nl/show/734982
Wirtschaftswissenschaftliches mit Rüdiger Bachmann und Christan Bayer. Migration Raffelhüschen: Ehrbarer Staat Werding: Migration und ihr Beitrag zum Staatshaushalt Mark Schieritz in der ZEIT (€) Unternehmensbesteuerung Gechert, Heimberger: Do corporate tax cuts boost economic growth? Ohrn: The Effect of Corporate Taxation on Investment and Financial Policy Link et.al.: Downward Revision of Investment Decisions after Corporate Tax […]
Wirtschaftswissenschaftliches mit Rüdiger Bachmann und Christan Bayer. Migration Raffelhüschen: Ehrbarer Staat Werding: Migration und ihr Beitrag zum Staatshaushalt Mark Schieritz in der ZEIT (€) Unternehmensbesteuerung Gechert, Heimberger: Do corporate tax cuts boost economic growth? Ohrn: The Effect of Corporate Taxation on Investment and Financial Policy Link et.al.: Downward Revision of Investment Decisions after Corporate Tax […]
Was bedeutet eigentlich „DWZ 978“? In dieser spannenden Folge lüftet Xenia Bayer das Geheimnis um die Deutsche Wertungszahl (DWZ) – die Zahl, die zeigt, wie stark du im Schach bist. Du erfährst: Wie die DWZ entsteht und was sie aussagt Warum sie mit Schulnoten vergleichbar ist – aber ohne Fünfen und Sechsen Wie du deine erste DWZ bekommst Was es mit der geheimnisvollen Ingo-Zahl auf sich hatte Und wie internationale Größen wie Magnus Carlsen oder Hou Yifan bewertet werden Dazu gibt's spannende Geschichten aus der Schachgeschichte, motivierende Zitate von Großmeistern wie Capablanca und Tartakower – und einen Blick in ein ganz besonderes Schachmuseum in Moskau. Folge direkt herunterladen ℹ Die besten Schachmaterialien im Chess Tigers Online Shop: Chess Tigers Shop
Before founding Bayer Strategic Consulting, Mark Bayer led communications on Capitol Hill for nearly two decades—helping politicians cut through noise, make arguments stick, and win support under pressure. These days, he brings that hard-earned clarity to a new crowd: scientists, researchers, and PhDs who need to get their message across in rooms that don't speak science.In Part One, Mark unpacks why so many highly educated experts still struggle to connect—and why messaging isn't about making things simpler, but sharper. He shares stories from Congress, contrasts the cultures of academia and advocacy, and reveals the single most important mindset shift for researchers who want to be heard.Key Highlights of Our Interview:First Day in Politics, First Misunderstanding“I thought ‘R&D' meant research and development. It meant Republicans and Democrats.”What getting thrown into the deep end of political culture taught him about insider language.The 8% Reality Check“Only 8% of PhDs stay in academia. But the training assumes 100% will.”Why the pipeline is broken—and who's getting left behind.From Data Dump to Message Discipline“Academics want to show the depth of their knowledge. But the real skill is answering the question in front of you.”How political strategy flips the communication playbook.Beauty Doesn't Equal Buy-In“You can build something beautiful. But if it doesn't solve a stakeholder's problem, it won't land.”Why relevance trumps brilliance.You've Got 10 Seconds“Start with the point. Don't make them dig for it.”Why headlines—not history lessons—open doors.Communication as a Career Lever“This isn't soft stuff. It's the stuff that gets you hired.”How learning to communicate is learning to lead._____________________Connect with us:Host: Vince Chan | Guest: Mark Bayer --Chief Change Officer--Change Ambitiously. Outgrow Yourself.Open a World of Expansive Human Intelligencefor Transformation Gurus, Black Sheep,Unsung Visionaries & Bold Hearts.EdTech Leadership Awards 2025 Finalist.20 Million+ All-Time Downloads.80+ Countries Reached Daily.Global Top 1.5% Podcast.Top 10 US Business.Top 1 US Careers.>>>180,000+ are outgrowing. Act Today.
You've got the credentials, the data, and the ideas. But how do you make people actually care?In Part Two, Mark unpacks his 11 Keys to Translating Complexity (complexitymadeclear.com) —an actionable framework to help scientists communicate clearly, concisely, and with impact. He explains why it's not about dumbing down your message but lifting it up so others can meet it. From the science of metaphor to the neuroscience of attention, Mark arms PhDs with tools to shift from overlooked to influential—without losing their intellectual edge.This episode is your field guide to getting heard, hired, and respected beyond the ivory tower.Key Highlights of Our Interview:The 11 Keys That Cut Through“People aren't persuaded by volume. They're moved by clarity.”Why precision—and not more PowerPoint slides—is your best communication strategy.Neuroscience for Nerds (And Everyone Else)“Our brains reward novelty. That's why metaphor works better than math in a pitch.”How attention works, and what science communicators can learn from it.PhDs Speak Another Language—Here's How to Translate“You're crossing cultures. Treat it like that.”Why business communication isn't just a tone shift—it's a worldview shift.Connection Before Communication“Until someone trusts you, they won't hear you.”The hidden role of empathy in making technical ideas land.AI Has Data. You Have Voice.“AI can't tell a story it hasn't seen. You can.”Why human communication still matters more than ever in a post-ChatGPT world._____________________Connect with us:Host: Vince Chan | Guest: Mark Bayer --Chief Change Officer--Change Ambitiously. Outgrow Yourself.Open a World of Expansive Human Intelligencefor Transformation Gurus, Black Sheep,Unsung Visionaries & Bold Hearts.EdTech Leadership Awards 2025 Finalist.20 Million+ All-Time Downloads.80+ Countries Reached Daily.Global Top 1.5% Podcast.Top 10 US Business.Top 1 US Careers.>>>180,000+ are outgrowing. Act Today.
Armbrüster, Tobias www.deutschlandfunk.de, Interviews
In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Philipp Vetter über Licht am Ende des Tunnels bei Bayer, Personalfrust bei der Telekom und den Deutschland-Besuch des Nvidia-Chefs. Außerdem geht es um Rheinmetall, Siemens Energy, T-Mobile US, Lockheed Martin, GameStop, Tesla, Starbucks, Alphabet, Chevron, Equinor und Eni. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html
Thu, 12 Jun 2025 03:45:00 +0000 https://jungeanleger.podigee.io/2328-inside-umbrella-powered-by-wikifolio-06-25-mit-19-ytd-hat-die-strategie-wieder-einen-proof-of-concept-geliefert-introducing-einstein 4a05fa4a2e053ad154826130ec9fad6e Folge 6 des Podcasts Inside Umbrella by wikifolio. Die Umbrella-Strategie, die steht für Richard Dobetsberger aka Ritschy, der auf Europas grösster Social Trading Plattform 2024 die 100 Mio. Euro Marke bei den Assets under Management überschritten hat und zum Asset Manager of the Year gewählt wurde. Wir senden 2025 an jedem 2. Donnerstag im Monat, damit im Zuge der Juni-Folge schon zum 6. Mal. Und es läuft: 19 Prozent year-to-date-Plus, 150 Mio. Euro AUM. Zum Stichtag sind 10 Positionen, angeführt von Rheinmetall, Bayer und Palantir, im wikifolio enthalten, Ritschy gibt zu jeder Position ein Update, weiters stellen wir Einstein vor nennen ein paar lässige Termine Anfang Juli. - Ritschy und Einstein: https://www.photaq.com/page/pic/97496 - Fragen zur Beantwortung in der Folge 7 am 10.7. dann: service@wikifolio.com oder christian.drastil@audio-cd.at - die bisherigen Folgen von Inside Umbrella: https://audio-cd.at/search/inside%20umbrella - https://www.wikifolio.com/de/at/p/ritschy?tab=about (dort findet man auch YouTube-Videos zur Strategie). - http://ritschydobetsberger.com - Börsepeople-Folge Richard Dobetsberger: https://audio-cd.at/page/podcast/6482 - wikifolio Rankings von aktuell mehr als 30.000: https://boerse-social.com/wikifolio/ranking - Sample Jingle: Shadowwalkers About / Risikohinweis: Christian Drastil wurde im Q4/24 in Frankfurt als "Finfluencer & Finanznetworker #1 Austria" ausgezeichnet. Der Jingle, der on the Job weiterentwickelt wird, basiert auf einem Sample der befreundeten Shadowwalkers, da werden wir ebenfalls einiges erzählen. Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple . 2328 full no Christian Drastil Comm.
Hello Rank Squad!The (first) Transfer Window has officially closed, but there's been plenty of activity on the managerial merry-go-round across Europe, with new faces taking over at new places - to the delight of some and the chagrin of others. On today's episode we're looking at a number of new bosses and analysing how we think they fit their new home. We start with the most recent appointment - Brentford's Thomas Frank is all set to take over at Tottenham Hotspur, who moved on from Ange Postecoglou at the end of last week, and try to build on that Europa League trophy that Ange won in what turned out to be his final game. We discuss the differing approaches and how this might all work out; before moving on to talk about Xabi Alonso's new era at Real Madrid, after he left Bayer Leverkusen to replace Carlo Ancelotti; and his replacement at Leverkusen - former Manchester United and Ajax gaffer Erik ten Hag. Then in Part Three, we get stuck into the Calcio Chaos - Christian Chivu replacing Simone Inzaghi at Inter; Max Allegri returning to AC Milan to take over from the sacked Sergio Conçeição; Gian Piero Gasperini leaving Atalanta to take over from Claudio Ranieri at Roma, with the Tinkerman turning down the Azzurri to stay upstairs in the Eternal City; and former Gasperini disciple Ivan Juric replacing the old chessmaster at Atalanta. There's some chat too about the Club World Cup and some of the transfers yet to happen this summer at the start of the show, and don't forget to take a look at our Patreon, where there's loads more transfer podcasts and newsletters happening over the course of this summer. It's Ranks! And remember, if you'd like more from the Rank Squad, including extra podcasts every Monday and Friday (including our weekly Postbox taking a look at the whole weekend of football) and access to our brilliant Discord community, then why not join us here on Patreon?
Ponemos la lupa sobre Inditex, Fnac Darty, Bayer, L'Oreal, con Xavier Brun, responsable de renta variable europea de Trea AM.
Red Bull's junior team is in open revolt as Racing Bulls fights to keep star rookie Isack Hadjar away from an early call-up.Climb the ladder with me on Patreon: https://patreon.com/lawvsThe battle for the future of Red Bull's F1 team is heating up, with Racing Bulls CEO Peter Bayer making it clear he won't let Isack Hadjar be rushed into the senior seat before he's ready. While Red Bull has a reputation for promoting young talent too quickly, Bayer wants Hadjar to have two full seasons at VCARB to truly understand F1's high-pressure world, develop his skills and contribute to the team's 2026 car. With Hadjar already smashing expectations and helping Racing Bulls bounce back into midfield relevance, the stakes couldn't be higher. Bayer's warning comes just as Arvid Lindblad secures his FIA superlicence, despite his age, which raises questions about Red Bull's next move with its impressive crop of juniors. With Racing Bulls is rebuilding its identity and setting a new standard for how young drivers should be nurtured, Isack's placement as its leader is critical.Why are Racing Bulls is pleading with Red Bull to break the cycle and avoid burning out another rising star? We break down the real reasons Hadjar should stay put, the risks of Red Bull's revolving-door policy and how this power struggle could shape the next era of F1...especially if Max Verstappen's future changes everything. #f1 #redbullracing #formula1 #f12025 #maxverstappen #yukitsunoda #liamlawson #isackhadjar #verstappen #tsunoda #hadjar #formulaone #f1updates #f1latest #redbull #f1drama #f1drivers #visacashapprb #vcarb #racingbulls
Bayer executives have been warning in recent weeks that after losing billions of dollars to Roundup case settlements and jury awards, they may be ready to give up the fight and get out of the glyphosate business. NAFB News ServiceSee omnystudio.com/listener for privacy information.
Alberto Iturralde, responsable de Operativa Dax, analiza los títulos de Redeia, Indra, Logista, Telefónica, Bayer o Solaria, entre otros
Sermon delivered on Pentecost Sunday, 2025, in Harrisburg, Pennsylvania, by Rev. Tobias Bayer. Epistle: Act. 2, 1-11. Gospel: St. John 14, 23-31.
Concluding their three-episode series filmed live in Chicago, your hosts wrap up the weekend with a discussion of the key bladder cancer presentations from the 2025 ASCO Annual Meeting. They begin in the perioperative space, reviewing updated CREST data presented since AUA and revisiting the NIAGARA trial last seen at ESMO 2024, and end by covering the latest EV-302 updates in the metastatic setting.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.
Picking up from Episode 23, your hosts turn their focus to the highly anticipated prostate cancer presentations from the 2025 ASCO Annual Meeting in Chicago. They begin with a discussion on mCSPC, focusing on the AMPLITUDE trial, followed by results from TALAPRO-2, the ARANOTE trial, IRONMAN, and STAMPEDE. The episode wraps with key abstracts and oral presentations on mCRPC.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.
Angel Studios https://Angel.com/ToddBecome a Premium Angel Studios Guild member to watch The King of Kings, stream all fan-curated shows and movies, and get 2 free tickets to every Angel Studios theatrical release. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bioptimizers https://Bioptimizers.com/toddEnter promo code TODD to get 10% off your order of Berberine Breakthrough today.Bizable https://GoBizable.comUntie your business exposure from your personal exposure with BiZABLE. Schedule your FREE consultation at GoBizAble.com today. Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. go to KnowYourRiskPodcast.com today.Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/ToddLISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeThe Elites have turned to waging a direct war on God's food that grows out of the ground. We'll talk about the ideological, and psychological “kill chute” tactics they use to corral the food market.Episode Links:“A lot of Farmers aren't able to grow their crops because of the Climate Crisis”. Bill Gates who is in part responsible for the Global Dimming of the Sun wants you to believe the Climate Crisis is responsible for reduced crop yields as he pushes his fake meat & insect foods.State lawmakers from NYC float bill to ban dairy farms from expanding beyond 700 cowsThese California and Colorado ballot measures are terrifying the meat industry; In Sonoma County and Denver, activists are putting animal welfare on the ballotKash Patel: New... I can confirm that the FBI arrested a Chinese national within the United States who allegedly smuggled a dangerous biological pathogen into the country.Grocery billionaire sticks his neck out for endangered ostriches…Eco-Fascism - 2026 Ballot Measure Seeks "End Of Farming" In Colorado4 companies control almost the entire US crop seed market. 2 companies, Bayer and Corteva alone account for over half of corn seed soldFarmer Ed Tate gives this succinct message to the Labour government & supermarkets. Farmers are not receiving a fair deal from either and therefore putting farmers' livelihoods at risk and our food security at risk. It's time for a fair deal for farmers.Newly elected Canadian PM Mark Carney: "We need to ultimately get to a point where every financial decision is taking climate change into account." "It's really about... backing [companies] who are part of the solution, and taking capital away from those who are part of the problem."
Bayer's herbicide Roundup has been subject to tens of thousands of lawsuits alleging the product causes cancer. A Missouri bill to shield Bayer from some of those lawsuits didn't pass during the spring legislative session, but it could be reintroduced in the future.
This episode covers: Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Recorded live in Chicago, your hosts explore the latest in kidney cancer, discussing new five-year follow-up data from KEYNOTE-564, the long-term results of CheckMate 214, insights from the ongoing PDIGREE trial, and much more.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.
Eduardo Bolinches, analista técnico de Invertia (El Español), repasa los títulos de Elecnor, Broadcom, Acciona, Iberpapel, Bayer o Puig
Hello Rank Squad! The footballing summer is officially here, with the Champions League Final crowning what has been a pretty unbelievable season in Europe all round. We start today's episode with the final word on that final, where Luis Enrique's brilliant PSG absolutely dismantled Inter in one of the all-time great showpiece performances. Then, it's onto the talk of the summer - transfer season; and whilst there will be plenty of this covered here on Ranks all summer long, we wanted to take a look at some of the deals already done or nearly done, that we have reservations about for one reason or another. Some are personal, some are club-related, and some are just a question of fit; but whilst there could and should be levels of excitement, it's important to try and be realistic as well. We discuss the details of moves for Rayan Cherki, Jobe Bellingham, Liam Delap and Matheus Cunha; and also touch on Bruno Fernandes' decision to stay at Manchester United. We finish off with a discussion of some of the deals we think are absolutely guaranteed to be a success, as well as some early thoughts on the links between Arsenal and Benjamin Sesko. It's Ranks! And remember, if you'd like more from the Rank Squad, including extra podcasts every Monday and Friday (including our weekly Postbox taking a look at the whole weekend of football) and access to our brilliant Discord community, then why not join us here on Patreon?
One of the many bills that didn't cross the finish line this past Missouri legislative session was one backed by agricultural giant Bayer. The bill would have shielded Bayer from liability in some lawsuits where its herbicide Roundup has been accused of causing cancer. With the end of the regular legislative session, the bill is dead for now. But as St. Louis Public Radio's Evy Lewis reports, it's likely not the last Missouri will hear of the issue.
What if innovation wasn't just for Research & Development? What if every employee had permission—and a process—to contribute game-changing ideas? In this episode of Build a Vibrant Culture podc, Nicole Greer sits down with Ben Bensaou, professor, innovation expert, and author of Built to Innovate, to explore the systems, habits, and cultural practices that embed innovation into a company's DNA.Together, they dive into:What it means to build an “innovating engine” alongside an “execution engine”How global companies like Bayer and WL Gore institutionalize innovationWhy giving employees “permission” is a non-negotiable for an innovative cultureThe power of listening not only to the voice—but the silence—of the customerWhy small ideas can spark massive organizational transformationIf you're a leader wondering how to shift your culture from status quo to breakthrough thinking, this episode is your blueprint.Connect with Ben!Book: https://a.co/d/7JOb1ZUEmail: ben.bensaou@insead.eduLinkedIn: https://www.linkedin.com/in/ben-m-bensaou/FB: https://www.facebook.com/people/Ben-M-Bensaou/100075875050792/X: https://x.com/BenBensaouYouTube: https://www.youtube.com/@benm.bensaou7167Learn more about Nicole Greer, the Vibrant Coach: https://www.vibrantculture.com/
No podcast ‘Notícia No Seu Tempo’, confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo’ desta terça-feira (03/06/2025): Embora o setor privado seja a favor da desburocratização das licenças ambientais, boa parte do empresariado brasileiro vê também riscos de aumento de judicialização, perda de investimentos e consequências ambientais e sociais negativas pela forma como tramitou no Congresso o projeto de lei que simplifica o licenciamento. “O projeto existe há anos, mas, em poucos dias, foram feitas alterações no texto sem a gente nem saber do que as emendas tratam”, diz Fernando Sampaio, diretor da Associação Brasileira das Indústrias Exportadoras de Carnes e integrante da Coalizão Brasil Clima, Florestas e Agricultura, que reúne empresas como JBS, Marfrig, Suzano e Bayer. Para Candido Bracher, ex-presidente do Itaú Unibanco, “houve exagero de flexibilização”. Aprovado no Senado, o projeto passará por nova votação na Câmara. E mais: Economia: Gasolina fica 5,6% mais barata para distribuidoras Política: Após testemunhas, Bolsonaro e outros 7 réus serão interrogados no Supremo Internacional: Rússia entrega plano de paz à Ucrânia; países acertam nova troca de presos Metrópole: Licitações atrasam e coletes vencidos comprometem ações policiais em SP Esportes: Ancelotti começa trabalho de dar identidade múltipla à seleção brasileiraSee omnystudio.com/listener for privacy information.
A scrappy six-foot, 143-pound stand-up comic and certified guy who does stuff, Tommy Bayer joins the pod this week. After hearing how Tommy is trying to put on weight so he can body more people on the court, Alex shares how he's the heel of his group chat. Alex recaps being invited to the Peach Pit show, sparking jealousy from Tommy—because Tommy does stuff. Drago talks about hanging out with the band backstage, which leads to a conversation about meeting other famous people. The boys also break down the difference between being invited places as a guy versus as a girl. Tommy reads some of the DMs he gets from men shooting their shot, Drago seeks advice for an upcoming date, and Tommy shares how he bounced back after a long-term relationship ended. Give Tommy a follow on Instagram: https://www.instagram.com/tommybayertime/?hl=en JOIN THE PATREON FOR A WEEKLY BONUS EPISODE AND EARLY ACCESS TO REGULAR EPISODES: https://www.patreon.com/youreanidiot Buy tickets to Alex's upcoming shows here: https://linktr.ee/alexdrag
In this episode of The Top Line, Fierce Biotech’s Chris Hayden sat down with Dr. Juergen Eckhardt of Bayer and Dr. Seth Ettenberg of BlueRock Therapeutics to discuss an innovative partnership that’s reshaping how big pharma teams up with biotech startups. BlueRock, a wholly owned subsidiary of Bayer, operates with the independence of a small biotech while benefiting from Bayer’s global reach and infrastructure. The “arm’s-length” model gives BlueRock the agility to innovate while leveraging Bayer’s resources in manufacturing, clinical trials and commercialization. The collaboration has already led to major milestones, including the development of a promising cell therapy for Parkinson’s disease, which is expected to enter Phase 3 trials later this year. “This isn’t just a partnership—it’s a relationship,” Eckhardt said. “We’re combining the best of both worlds: biotech speed and pharma scale.” The episode also explores how Bayer’s experience in biologics manufacturing has helped BlueRock overcome one of regenerative medicine’s biggest challenges—scaling complex cell therapies. The model has proven so effective that Bayer has since replicated it with other companies, signaling a broader shift in how the company approaches innovation. To learn more about this unique partnership and what it means for the future of neurological disease treatment, listen to the full episode of The Top Line.See omnystudio.com/listener for privacy information.
Jobe Bellingham hat sich wohl für den BVB entschieden. Bei einigen DFB-Stars ist die Zukunft in diesem Sommer ungewiss und Bayer Leverkusen hat ein erstes Angebot vom FC Liverpool abgelehnt.
Sermon delivered on the Fourth Sunday After Easter, 2025, in Hammond, Louisiana and Richmond, Texas, by Rev. Tobias Bayer. Epistle: St. James 1, 17-21. Gospel: St. John 16, 5-14.
Sermon delivered on the Sunday Within the Octave of the Ascension, 2025, in Pottstown, Pennsylvania, by Rev. Tobias Bayer. Epistle: 1 Peter 4, 7-11. Gospel: St. John 15, 26-27; 16, 1-4.
Julian Nagelsmann hat kurz vor dem Nations-League-Halbfinale mit Verletzungssorgen zu kämpfen. Bayer Leverkusen steht kurz vor der Verpflichtung eines alten Bekannten aus der Bundesliga und der FSV Mainz hat mit Benedict Hollerbach einen neuen Angreifer.
Wir haben zwei Probleme: Erik ten Hag wurde erst nach unserer Aufnahme offiziell neuer Leverkusen-Trainer. Und Ole Werner hat sich auch erst danach dazu entschieden, Werder Bremen nächstes Jahr zu verlassen. Wir haben aber trotzdem ausführlich über die Bundesliga gesprochen: Über den Pokalsieger VfB Stuttgart, über den FC Bayern nach der Absage von Florian Wirtz und den FC Augsburg, der an Sandro Wagner baggert. Außerdem: Wie gut spielt eigentlich der schottische Goretzka in Neapel? Und war das nicht insgesamt eine geile Saison? Hört rein und diskutiert gerne mit!
Zwei News kamen zu spät für die heutige Folge: Ten Hag ist jetzt offiziell bei Leverkusen und Ole Werner verlässt Werder 2026. Trotzdem gibt's viel Bundesliga auf die Ohren: Pokalsieger Stuttgart, Wirtz' Bayern-Absage und der Wagner-Flirt in Augsburg.
Die Themen: Norweger wacht mit Containerschiff im Garten auf; SPD muss Otto-Wels-Saal nicht an AfD abgeben; Merkel kritisiert Grenzkontrollen; Jeder Vierte hat Einwanderungsgeschichte; Harvard darf keine ausländischen Studenten mehr aufnehmen; Getöteter Botschaftsmitarbeiter Israels war Bayer; Rheingold-Studie sieht Verbundenheitskrise; Hohe Erwartungen an Berlins neue Kultursenatorin und Kim Kardashian ist jetzt offiziell Anwältin. Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/ApokalypseundFilterkaffee
Mais um VACILO NEWS no ar! E hoje Daniel Bayer e João Carvalho te deixam super informado a respeito de carros sexualmente vulneráveis, casamentos de diversão e araras fumantes!FINANCIE ESTE VACILO:apoia.se/decrepitosAssine o plano BOGA VIVA e participe do nosso GRUPO SECRETO NO TELEGRAM!MANDA PIX:livepix.gg/decrepitosPARTICIPE PELO E-MAIL:ouvinte@decrepitos.comANUNCIE COM A GENTE:comercial@decrepitos.com
Ed Bushaw joins us to discuss the upcoming Knights of Columbus Boston Butt sale, Andrea Picotti-Bayer on three compelling Catholic court cases, and Dr. Matthew Brunson on his new biography on Pope Leo XIV.
While few doubt the opportunity represented by real-world evidence, some concerns remain about its validity compared to traditional forms of clinical evidence, particularly among regulators. To address these concerns, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, suggests that incorporating some elements of traditional trials, such as randomization, is a good way to persuade regulators that RWE can be used for consumer health innovation, for example in generating new claims or supporting Rx-to-OTC switch. Looking forward, Spitzer is excited about the ways in which digital health tools and artificial intelligence can be used to expand the scope of RWE as well as drive personalization for consumers. Timestamps: 3:00 - Addressing concerns about RWE's scientific rigour and validity 12:00 – Regulators' views of RWE, particularly for consumer health 16:00 – Use of RWE for Rx-to-OTC switch 22:00 – The future of RWE Guest Bio: Volker Spitzer has more than 30 years of R&D experience spanning the consumer health sector, ingredients industry, and academia. Beginning his career as a professor in pharmaceutical sciences, he ascended to global positions encompassing R&D, innovation, licensing/M&A, and medical marketing at firms like Roche, DSM Nutritional Products, and Bayer. Since October 2017, Spitzer has been affiliated with IQVIA Consumer Health, serving as the vice president for global R&D and RWE Services. His purview primarily includes clinical research, RWE, virtual trials, and the burgeoning field of digital health. He has penned over 80 scientific publications, whitepapers and textbooks centered on science and innovation.
Glyphosate is a toxic carcinogenic chemical found in RoundUp, a weedkiller that is routinely sprayed on our lawns and crops. But the bad news doesn't stop there! It is making its way into the food we eat, the air, and the water. Worse still, the maker of glyphosate, Bayer, is working on passing liability shield legislation so that they cannot be sued for the way the poison in their products is affecting the nation! Today, Kelly Ryerson, known as the Glyphosate Girl, explains why she is working so hard to inform the public about the dangers of glyphosate and the company that wants to protect itself from the fallout of the harm it is causing. Kelly goes over the legislation that is being considered in various states across the country. She also explains why glyphosate is so damaging, how it personally affected her own life, and how a General Mills whistleblower helped her to connect the dots about it all. Update: The liability legislation being considered in North Dakota, at the time of the interview, has since been passed in that state. Visit Kelly's websites: americanregeneration.org and glyphosatefacts.com Become a member of the Weston A. Price Foundation (and use the code pod10) Check out our sponsors: Arvoti and Lumiram
Why is the timing of a fungicide application so important? Dr. Megan Taylor is in the podcast room with our hosts Jeff Jarrett and Sal Sama for this episode of The High Ground powered by Premier Companies. Dr. Taylor is the Technical Agronomist at Bayer, and as a fun fact, she is a former colleague of Sal's!Dr. Taylor will share about her educational background and what eventually led to her working for Bayer. You'll learn about the changes that have occurred in the world of fungicides over the last decade including emerging diseases and how planting practices have changed application needs. You'll learn about best application practices for growers who need to cover a lot of acres and what will give you the biggest bang for your buck to protect your yield potential. Struggling with stink bugs not just in your field but in your home as well? Dr. Taylor will share her thoughts on those as well, and if you are looking for fungicide data, head on over to the wealth of knowledge at https://cropprotectionnetwork.org/.
© 2020-2025 Ivy Podcast Discovery LLC
